Stock ALKS ALKERMES PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alkermes plc

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
24.68 USD +0.98% Intraday chart for Alkermes plc +3.48% -11.03%
Apr. 09 Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday MT
Apr. 09 Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,213 3,175 3,761 4,293 4,629 4,175 - -
Enterprise Value (EV) 1 2,956 2,790 3,291 3,847 4,107 3,385 3,005 2,837
P/E ratio -16.3 x -28.5 x -77.5 x -26.9 x 13.2 x 12.1 x 13.4 x 14 x
Yield - - - - - - - -
Capitalization / Revenue 2.74 x 3.06 x 3.2 x 3.86 x 2.78 x 2.75 x 2.74 x 2.69 x
EV / Revenue 2.52 x 2.69 x 2.8 x 3.46 x 2.47 x 2.23 x 1.97 x 1.83 x
EV / EBITDA -21.9 x -38.2 x 66.7 x -59.7 x 8.44 x 6.97 x 6.33 x 5.11 x
EV / FCF -157 x 68.7 x 44.7 x -224 x 11.6 x 8.26 x 7.42 x 5.69 x
FCF Yield -0.64% 1.46% 2.24% -0.45% 8.6% 12.1% 13.5% 17.6%
Price to Book 2.97 x 2.97 x 3.36 x 4.11 x 3.85 x 2.33 x 1.95 x 1.67 x
Nbr of stocks (in thousands) 157,522 159,150 161,705 164,312 166,881 169,184 - -
Reference price 2 20.40 19.95 23.26 26.13 27.74 24.68 24.68 24.68
Announcement Date 2/13/20 2/11/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,171 1,039 1,174 1,112 1,663 1,519 1,525 1,551
EBITDA 1 -135.1 -72.98 49.37 -64.4 486.7 485.9 474.5 555.1
EBIT 1 -175.5 -112.4 -29.29 -142.3 414.1 420.8 411.6 449.8
Operating Margin -14.99% -10.82% -2.5% -12.8% 24.9% 27.71% 27% 29%
Earnings before Tax (EBT) 1 -197.1 -96.54 -39.31 -167.3 421.5 427.7 424.2 421.1
Net income 1 -196.6 -110.9 -48.17 -158.3 355.8 352.1 331.1 328.5
Net margin -16.79% -10.67% -4.1% -14.24% 21.39% 23.18% 21.71% 21.18%
EPS 2 -1.250 -0.7000 -0.3000 -0.9700 2.100 2.040 1.847 1.762
Free Cash Flow 1 -18.86 40.62 73.7 -17.21 353.3 410 404.8 498.6
FCF margin -1.61% 3.91% 6.28% -1.55% 21.24% 27% 26.55% 32.14%
FCF Conversion (EBITDA) - - 149.28% - 72.59% 84.38% 85.32% 89.82%
FCF Conversion (Net income) - - - - 99.31% 116.46% 122.29% 151.79%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/11/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 294.1 324.5 278.5 276.2 252.4 304.7 287.6 617.4 380.9 377.5 362.6 391.3 384.5 376 360.9
EBITDA 1 -10.04 23.53 -7.388 -25.39 -51.48 -0.907 -38.69 66.97 78.09 72.85 113.7 134.6 112.8 102.4 -
EBIT 1 -19.66 2.383 -26.58 -34.46 -60.64 -20.58 -47.49 239.2 43.85 54.63 95.26 120.4 112.3 105.2 107.3
Operating Margin -6.68% 0.73% -9.54% -12.47% -24.03% -6.76% -16.51% 38.74% 11.51% 14.47% 26.27% 30.77% 29.22% 27.98% 29.73%
Earnings before Tax (EBT) 1 -26.54 0.227 -45 -33.25 -67.37 -21.69 -47.86 239.8 47.36 58.32 88.93 110.8 119.6 120.3 -
Net income 1 -28.99 0.873 -35.9 -30.14 -63.97 -28.25 -41.84 237.1 47.76 112.8 74.94 92.92 89.94 85.52 -
Net margin -9.86% 0.27% -12.89% -10.91% -25.35% -9.27% -14.55% 38.4% 12.54% 29.88% 20.66% 23.75% 23.39% 22.74% -
EPS 2 -0.1800 0.0100 -0.2200 -0.1800 -0.3900 -0.1700 -0.2500 1.380 0.2800 0.6600 0.4401 0.5435 0.5257 0.4955 -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/27/21 2/16/22 4/27/22 7/27/22 11/2/22 2/16/23 4/26/23 7/26/23 10/25/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 258 385 470 447 523 791 1,170 1,338
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -18.9 40.6 73.7 -17.2 353 410 405 499
ROE (net income / shareholders' equity) 9.94% 6.38% 11.8% 5.37% 21.7% 27.6% 20.6% 18.1%
ROA (Net income/ Total Assets) 6.18% 3.66% 6.5% 2.9% 11.9% 20.2% 17.3% 14.5%
Assets 1 -3,181 -3,032 -741.4 -5,455 2,993 1,745 1,909 2,262
Book Value Per Share 2 6.880 6.720 6.910 6.350 7.200 10.60 12.60 14.80
Cash Flow per Share 2 0.4600 0.5200 0.6300 0.1300 2.360 3.080 2.870 -
Capex 1 90.9 42.2 28 38.3 48 40.7 38.7 38.2
Capex / Sales 7.77% 4.06% 2.39% 3.44% 2.89% 2.68% 2.54% 2.46%
Announcement Date 2/13/20 2/11/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alkermes plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
24.68 USD
Average target price
35.25 USD
Spread / Average Target
+42.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALKERMES PLC Stock Alkermes plc
-11.03% 4.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALKS Stock
  4. Financials Alkermes plc